Frazier Lifesciences Acquisition Corporation
FLAC
NASDAQ Capital Market9.87
USD
+0.28
- -
CIK
0001828326
ISIN
KYG3710A1058
Return %
Stock
S&P500
1Y
0.71
18.02
3Y
-8.61
64.11
5Y
-8.61
72.15
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- Two Union Square Seattle WA United States of America 98101
- IPO Date
- Feb 8, 2021
- CIK
- 0001828326
- Similar Companies
- Business
- Frazier Lifesciences Acquisition Corporation (FLAC) operates as a blank check company focused on effecting mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations with one or more businesses or entities in the biotechnology sector; it offers no independent products or services beyond its special purpose acquisition structure. Incorporated in 2020 as a Cayman Islands exempted company and headquartered in Seattle, Washington, FLAC targets healthcare and lifesciences opportunities globally, leveraging the expertise of its sponsor, an affiliate of Frazier Healthcare Partners. In November 2022, FLAC completed its initial business combination with NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical firm developing obicetrapib, a next-generation CETP inhibitor for cardiovascular disease; the merger provided approximately $470 million in pro forma cash, resulted in a $326 million enterprise value, and led to the combined entity's Nasdaq listing under tickers NAMS and NAMSW, with FLAC units separating into ordinary shares and warrants.